| Title |
Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness
|
|---|---|
| Published in |
PharmacoEconomics, January 2013
|
| DOI | 10.1007/s40273-012-0017-2 |
| Pubmed ID | |
| Authors |
Martin Frank, Thomas Mittendorf |
| Abstract |
Metastatic colorectal cancer (mCRC) imposes a substantial health burden on individual patients and society. Furthermore, rising costs in oncology cause a growing concern about reimbursement for innovations in this sector. The promise of pharmacogenomic profiling and related stratified therapies in mCRC is to improve treatment efficacy and potentially save costs. Among other examples, the commonly used epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab are only effective in patients with kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type cancers. Hence, the adaptation of predictive biomarker testing might be a valid strategy for healthcare systems worldwide. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| United Kingdom | 1 | <1% |
| India | 1 | <1% |
| Estonia | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 98 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 22% |
| Student > Master | 13 | 13% |
| Other | 10 | 10% |
| Student > Ph. D. Student | 10 | 10% |
| Student > Bachelor | 8 | 8% |
| Other | 24 | 23% |
| Unknown | 16 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 36% |
| Economics, Econometrics and Finance | 11 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Business, Management and Accounting | 5 | 5% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 21 | 20% |
| Unknown | 18 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2020.
All research outputs
#6,203,921
of 22,693,205 outputs
Outputs from PharmacoEconomics
#687
of 1,813 outputs
Outputs of similar age
#67,324
of 279,188 outputs
Outputs of similar age from PharmacoEconomics
#7
of 23 outputs
Altmetric has tracked 22,693,205 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,813 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,188 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.